Celcuity Inc. — 2022 Form 10-K Summary
Business context and reporting period
Celcuity is a clinical-stage biotechnology company developing targeted cancer therapies and companion diagnostics. Its lead drug candidate, gedatolisib, is a pan-PI3K/mTOR inhibitor licensed exclusively worldwide from Pfizer; its CELsignia platform analyzes live tumor cells to identify abnormal signaling pathways. This filing reports the fiscal year ended December 31, 2022. The supplied filing presents annual results, not separate fourth-quarter financial statements.
Financial and operating performance
- Revenue: None to date. The company has not generated product or other revenue.
- Profit and expenses: Net loss was $40.4 million, versus $29.6 million in 2021, a 36% increase. Operating loss was $39.4 million. Research and development expense rose 37% to $35.3 million; general and administrative expense rose 58% to $4.1 million. With no revenue, operating margins are not meaningful.
- Cash flow: Cash used in operating activities was $36.0 million, compared with $20.3 million in 2021. Investing activities used $144.0 million, primarily for short-term government securities. Financing activities provided $120.3 million.
- Liquidity: At year-end, cash and cash equivalents were $24.6 million and short-term investments were $144.0 million, totaling approximately $168.6 million. Current assets were $175.2 million and current liabilities were $6.9 million.
- Debt: $35.0 million of Innovatus loan principal was outstanding; its balance-sheet carrying value was approximately $35.0 million. The secured loan matures in April 2027, bears interest at a variable rate, and includes additional milestone- and covenant-conditioned borrowing tranches.
- Other balance-sheet items: Total assets were $175.7 million, total liabilities $41.9 million, stockholders’ equity $133.8 million, and accumulated deficit $96.3 million.
Material changes versus 2021
- Net loss increased by $10.8 million. R&D spending increased as existing clinical trials continued and the company initiated its Phase 3 program; 2021 R&D included a $10.0 million Pfizer license fee, while 2022 did not.
- Operating cash use increased by $15.7 million. The company shifted substantial cash into short-term investments, which were $144.0 million at year-end versus none in 2021.
- Celcuity raised approximately $100 million gross in a December private placement and $5.2 million gross through its at-the-market offering. The private placement included common and convertible preferred shares plus warrants, creating potential dilution.
- Debt principal increased from $15 million to $35 million following a $20 million Innovatus draw in December.
Outlook, commentary, risks, and unusual items
- VIKTORIA-1, an international randomized Phase 3 trial in HR+/HER2-negative advanced breast cancer after CDK4/6 therapy, began dosing its first patient in December 2022. It is planned to enroll approximately 701 patients and compares gedatolisib-based regimens with control treatments in separate PIK3CA groups.
- Gedatolisib received FDA Fast Track and Breakthrough Therapy designations in 2022. These designations do not assure faster approval or eventual approval. The filing reports encouraging Phase 1b results, including response and safety data, but these are preliminary clinical results and do not establish Phase 3 efficacy.
- Four CELsignia-related Phase 2 trials are underway with pharmaceutical and clinical collaborators. Celcuity reported COVID-related enrollment delays and expected interim FACT-1 and FACT-2 results in the second half of 2023.
- Management expects R&D and G&A expenses to rise as trials and development advance, with sales and marketing spending increasing if commercialization approaches. Management’s MD&A says cash, investments, and available Innovatus borrowings are expected to fund operations through at least 2025; the liquidity note separately states that cash and investments on hand cover the current operating plan for at least 12 months from the report’s issuance. Actual spending or financing availability could differ.
- Key risks include clinical-trial failure or delay, patient enrollment, regulatory approval, dependence on Pfizer-licensed intellectual property and third-party manufacturers, CELsignia validation and commercial adoption, reimbursement uncertainty, competition, and need for future capital. The company has no commercial revenue and has not completed a registrational trial.
- The Pfizer license includes up to $335 million in development and commercial milestone payments and tiered royalties in the low-to-mid-teens on future gedatolisib sales. These are contingent obligations, not current operating expenses.
- The financial statements received an unqualified audit opinion; the auditor reported no critical audit matters. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end.
Important facts for investors to verify
- VIKTORIA-1 enrollment, timing, protocol, and eventual primary-endpoint results, including comparisons by PIK3CA status.
- Whether the company’s stated runway through at least 2025 remains achievable, including the conditions and availability of undrawn Innovatus tranches.
- Potential dilution from preferred-stock conversion, warrants, options, and future equity financing; the filing reports 21.7 million common shares outstanding at December 31, 2022.
- Progress and timing of CELsignia trial results, partner commitments, regulatory requirements, and reimbursement evidence.
- Gedatolisib’s full license economics and secured-loan terms, including milestone payments, royalties, variable interest, covenants, and prepayment provisions.